Enhancing siRNA effects in T cells for adoptive immunotherapy

Kevin Morris, Daniela Castanotto, Zaid Al-Kadhimi, Michael Jensen, John Rossi, Laurence J.N. Cooper

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Genetically manipulated T cells can be endowed with novel functions to obtain desired in vivo effects after adoptive transfer. This genetic approach is being used to introduce genes such as chimeric immunoreceptors and tumor-specific T cells are being evaluated in early phase clinic trials. However, the ability to alter the genetic programming of T cells also presents opportunities to remove unwanted T-cell functions in order to augment an anti-tumor effect or endow resistance such as to HIV infection. Specifically, the use of RNA interference (RNAi) to disrupt gene expression by targeting either the mRNA or the promoter, provides investigators with many new opportunities to genetically modify T cells that should prove useful in future applications of adoptive immunotherapy.

Original languageEnglish (US)
Pages (from-to)461-467
Number of pages7
JournalHematology
Volume10
Issue number6
DOIs
StatePublished - Dec 1 2005

Fingerprint

Adoptive Immunotherapy
Small Interfering RNA
T-Lymphocytes
Gene Targeting
Adoptive Transfer
RNA Interference
HIV Infections
Neoplasms
Research Personnel
Gene Expression
Messenger RNA
Genes

Keywords

  • Immunotherapy
  • RNA interference
  • T cells
  • siRNA

ASJC Scopus subject areas

  • Hematology

Cite this

Morris, K., Castanotto, D., Al-Kadhimi, Z., Jensen, M., Rossi, J., & Cooper, L. J. N. (2005). Enhancing siRNA effects in T cells for adoptive immunotherapy. Hematology, 10(6), 461-467. https://doi.org/10.1080/10245330500233569

Enhancing siRNA effects in T cells for adoptive immunotherapy. / Morris, Kevin; Castanotto, Daniela; Al-Kadhimi, Zaid; Jensen, Michael; Rossi, John; Cooper, Laurence J.N.

In: Hematology, Vol. 10, No. 6, 01.12.2005, p. 461-467.

Research output: Contribution to journalReview article

Morris, K, Castanotto, D, Al-Kadhimi, Z, Jensen, M, Rossi, J & Cooper, LJN 2005, 'Enhancing siRNA effects in T cells for adoptive immunotherapy', Hematology, vol. 10, no. 6, pp. 461-467. https://doi.org/10.1080/10245330500233569
Morris K, Castanotto D, Al-Kadhimi Z, Jensen M, Rossi J, Cooper LJN. Enhancing siRNA effects in T cells for adoptive immunotherapy. Hematology. 2005 Dec 1;10(6):461-467. https://doi.org/10.1080/10245330500233569
Morris, Kevin ; Castanotto, Daniela ; Al-Kadhimi, Zaid ; Jensen, Michael ; Rossi, John ; Cooper, Laurence J.N. / Enhancing siRNA effects in T cells for adoptive immunotherapy. In: Hematology. 2005 ; Vol. 10, No. 6. pp. 461-467.
@article{dee222616f6d4afba3999db12fae7222,
title = "Enhancing siRNA effects in T cells for adoptive immunotherapy",
abstract = "Genetically manipulated T cells can be endowed with novel functions to obtain desired in vivo effects after adoptive transfer. This genetic approach is being used to introduce genes such as chimeric immunoreceptors and tumor-specific T cells are being evaluated in early phase clinic trials. However, the ability to alter the genetic programming of T cells also presents opportunities to remove unwanted T-cell functions in order to augment an anti-tumor effect or endow resistance such as to HIV infection. Specifically, the use of RNA interference (RNAi) to disrupt gene expression by targeting either the mRNA or the promoter, provides investigators with many new opportunities to genetically modify T cells that should prove useful in future applications of adoptive immunotherapy.",
keywords = "Immunotherapy, RNA interference, T cells, siRNA",
author = "Kevin Morris and Daniela Castanotto and Zaid Al-Kadhimi and Michael Jensen and John Rossi and Cooper, {Laurence J.N.}",
year = "2005",
month = "12",
day = "1",
doi = "10.1080/10245330500233569",
language = "English (US)",
volume = "10",
pages = "461--467",
journal = "Hematology",
issn = "1024-5332",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Enhancing siRNA effects in T cells for adoptive immunotherapy

AU - Morris, Kevin

AU - Castanotto, Daniela

AU - Al-Kadhimi, Zaid

AU - Jensen, Michael

AU - Rossi, John

AU - Cooper, Laurence J.N.

PY - 2005/12/1

Y1 - 2005/12/1

N2 - Genetically manipulated T cells can be endowed with novel functions to obtain desired in vivo effects after adoptive transfer. This genetic approach is being used to introduce genes such as chimeric immunoreceptors and tumor-specific T cells are being evaluated in early phase clinic trials. However, the ability to alter the genetic programming of T cells also presents opportunities to remove unwanted T-cell functions in order to augment an anti-tumor effect or endow resistance such as to HIV infection. Specifically, the use of RNA interference (RNAi) to disrupt gene expression by targeting either the mRNA or the promoter, provides investigators with many new opportunities to genetically modify T cells that should prove useful in future applications of adoptive immunotherapy.

AB - Genetically manipulated T cells can be endowed with novel functions to obtain desired in vivo effects after adoptive transfer. This genetic approach is being used to introduce genes such as chimeric immunoreceptors and tumor-specific T cells are being evaluated in early phase clinic trials. However, the ability to alter the genetic programming of T cells also presents opportunities to remove unwanted T-cell functions in order to augment an anti-tumor effect or endow resistance such as to HIV infection. Specifically, the use of RNA interference (RNAi) to disrupt gene expression by targeting either the mRNA or the promoter, provides investigators with many new opportunities to genetically modify T cells that should prove useful in future applications of adoptive immunotherapy.

KW - Immunotherapy

KW - RNA interference

KW - T cells

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=31144463930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31144463930&partnerID=8YFLogxK

U2 - 10.1080/10245330500233569

DO - 10.1080/10245330500233569

M3 - Review article

C2 - 16321811

AN - SCOPUS:31144463930

VL - 10

SP - 461

EP - 467

JO - Hematology

JF - Hematology

SN - 1024-5332

IS - 6

ER -